Li Fang, Liu Zihao, Huang Kaibin, Ding Shunkai, Zhu Chang, Fu Yuxiang, Sun Xiao, Zhang Shipai, Zhang Rui, Jiang Zhipeng, Zhong Keli, Zheng Qijun
Department of Gastrointestinal Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China, 518020.
Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan, China.
J Cancer. 2025 Jun 12;16(8):2737-2749. doi: 10.7150/jca.101892. eCollection 2025.
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Our study delves into the molecular intricacies of CRC by analyzing gene expression profiles across multiple datasets, revealing significant gene alterations that distinguish CRC from normal tissues. We identified Stanniocalcin-2 (STC2) as a key regulator in CRC, associated with poor prognosis, survival outcomes and cancer cell proliferation or invasion. Through comprehensive data mining of the Gene Expression Omnibus (GEO), the European Bioinformatics Institute (EMBL-EBI), and The Cancer Genome Atlas (TCGA), we emphasized the role of STC2 in tumorigenesis. Our pan-cancer analysis established STC2's involvement in various cancer types, underscoring its potential as a universal biomarker. Additionally, we performed experimental research and found STC2 is significantly upregulated in CRC tissue and can promote CRC progression by regulating cancer cell invasion and proliferation. This study provides valuable insights into the oncogenic role of STC2, proposing it as a promising target for therapeutic intervention and a marker for aggressive cancer phenotypes.
结直肠癌（CRC）仍然是全球癌症相关死亡的主要原因。我们的研究通过分析多个数据集的基因表达谱，深入探究了CRC的分子复杂性，揭示了区分CRC与正常组织的显著基因改变。我们确定了Stanniocalcin-2（STC2）是CRC中的关键调节因子，与预后不良、生存结果以及癌细胞增殖或侵袭相关。通过对基因表达综合数据库（GEO）、欧洲生物信息学研究所（EMBL-EBI）和癌症基因组图谱（TCGA）进行全面的数据挖掘，我们强调了STC2在肿瘤发生中的作用。我们的泛癌分析确定了STC2参与多种癌症类型，突出了其作为通用生物标志物的潜力。此外，我们进行了实验研究，发现STC2在CRC组织中显著上调，并可通过调节癌细胞侵袭和增殖促进CRC进展。本研究为STC2的致癌作用提供了有价值的见解，提出其作为治疗干预的有前景靶点和侵袭性癌症表型的标志物。
